- Home
- REVB vs SYRA Comparison
REVB vs SYRA Comparison
Compare REVB & SYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REVB
- SYRA
- Stock Information
- Founded
- REVB 2020
- SYRA 2020
- Country
- REVB United States
- SYRA United States
- Employees
- REVB N/A
- SYRA N/A
- Industry
- REVB Biotechnology: Pharmaceutical Preparations
- SYRA Other Specialty Stores
- Sector
- REVB Health Care
- SYRA Industrials
- Exchange
- REVB Nasdaq
- SYRA Nasdaq
- Market Cap
- REVB 5.4M
- SYRA 5.9M
- IPO Year
- REVB N/A
- SYRA 2023
- Fundamental
- Price
- REVB $0.40
- SYRA $0.49
- Analyst Decision
- REVB
- SYRA
- Analyst Count
- REVB 0
- SYRA 0
- Target Price
- REVB N/A
- SYRA N/A
- AVG Volume (30 Days)
- REVB 6.8M
- SYRA 4.8M
- Earning Date
- REVB 11-08-2024
- SYRA 10-29-2024
- Dividend Yield
- REVB N/A
- SYRA N/A
- EPS Growth
- REVB N/A
- SYRA N/A
- EPS
- REVB N/A
- SYRA N/A
- Revenue
- REVB N/A
- SYRA $7,741,558.00
- Revenue This Year
- REVB N/A
- SYRA $47.74
- Revenue Next Year
- REVB N/A
- SYRA N/A
- P/E Ratio
- REVB N/A
- SYRA N/A
- Revenue Growth
- REVB N/A
- SYRA 35.47
- 52 Week Low
- REVB $0.28
- SYRA $0.34
- 52 Week High
- REVB $25.26
- SYRA $8.37
- Technical
- Relative Strength Index (RSI)
- REVB 39.87
- SYRA 51.88
- Support Level
- REVB $0.39
- SYRA $0.45
- Resistance Level
- REVB $0.53
- SYRA $0.55
- Average True Range (ATR)
- REVB 0.13
- SYRA 0.10
- MACD
- REVB 0.00
- SYRA -0.00
- Stochastic Oscillator
- REVB 7.54
- SYRA 20.67
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
About SYRA Syra Health Corp.
Syra Health Corp is a healthcare services company promoting preventative health, holistic wellness, health education, and equitable healthcare for all patient demographics. The company leverages deep scientific and healthcare expertise to create strategic frameworks and develop patient-centric solutions for the betterment of patient lives and health outcome linked to developing a healthier population. It strives to offer comprehensive end-to-end solutions in health education services, population health management, behavioral and mental health, healthcare workforce and digital health.